Avista's mission is to develop innovative gene therapies for retinal diseases, including rare, inherited conditions that have a profound impact on patients' quality of life. We leverage our computationally guided scAAVengr platform to generate and validate a toolkit of proprietary AAV vectors that overcome the most significant obstacles to effective gene therapies, including cell-type specific delivery, reduced dosages, and efficient expression, using a minimally invasive intravitreal approach. Our quantitative, in vivo-based approach and clinical ophthalmology expertise allow us to rapidly translate new gene therapies to the clinic. Avista is a UPMC Enterprises portfolio company founded based on the research of Drs. Leah Byrne, Jose Sahel, and Paul Sieving.